EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma



Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma



Anticancer Research 20(5a): 3045-3049



Background: Matrix Metalloproteinases (MMPs) have been implicated as playing an important role in cancer invasion and metastasis. MMPs have been identified in a wide variety of malignancies including head and neck squamous cell carcinomas (HNSCC). Material and Methods: We investigated the circulating level of MMP-2 (gelatinase A or 72-kD type IV collagenase) and MMP-9 (gelatinase B or 92-kD type IV collagenase) in sera from patients with various head and neck squamous cell carcinomas (n=86) as well as from healthy normal controls (n=47). Serum MMP concentrations were determined as serum immunoreactivity by using a quantitative sandwich enzyme immunoassay technique. For statistical analysis, the t-test and Kruskal-Wallis test were performed. Results: The majority of the patients with HNSCC were found to have high concentrations of serum MMP-9. The levels of MMP-9 in the sera of patients with cancer ranged from 39 to 1547 ng/ml (mean, 417 ng/ml). In contrast, the MMP-9 serum levels in 47 healthy individuals ranged from 30 to 537 ng/ml (mean, 189 ng/ml), MMP-9 serum concentration being significantly higher in HNSCC patients (p=0.001). MMP-9 serum concentrations of patients with advanced stage HNSCC were significantly higher (p=0.0449) compared to patients with early stage cancer. No significant difference of MMP-2 serum levels was seen when comparing HNSCC patients and normal controls. Conclusion: The present data indicate that the elevation of serum levels of MMP-9, but not MMP-2, may be a useful marker for clinical monitoring of HNSCC patients.

(PDF emailed within 1 workday: $29.90)

Accession: 011348873

Download citation: RISBibTeXText

PMID: 11062721



Related references

Serum Level of Matrix Metalloproteinase-9 in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Laboratory 62(8): 1569-1574, 2017

Elevated serum levels of matrix metalloproteinase-3 and -8 in patients with squamous cell carcinomas of the head and neck. Journal of Cancer Research & Clinical Oncology 127(Supplement 1): S58, 2001

Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. International Journal of Cancer 116(3): 422-427, 2005

Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Human Pathology 31(8): 895-904, 2000

Postoperative sequential changes of serum levels of matrix metalloproteinase and tissue inhibitor of metalloproteinase in Japanese patients with the squamous cell carcinoma of esophagus. Proceedings of the American Association for Cancer Research Annual Meeting 40: 346, March, 1999

Matrix metalloproteinase-2 concentrations in squamous cell carcinoma of the head and neck and its clinical significance. Nihon Jibiinkoka Gakkai Kaiho 99(2): 299-305, 1996

Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Letters 211(1): 19-24, 2004

Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC). European Review for Medical and Pharmacological Sciences 18(4): 509-515, 2015

Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clinical Cancer Research 10(9): 3110-3116, 2004

Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer. Oral Oncology 46(7): 514-518, 2011

Early Detection of Serum Levels of HER-2 in Patients with Head and Neck Squamous Cell Carcinoma. Iranian Journal of Otorhinolaryngology 25(72): 161-168, 2013

Serum nitric oxide levels in patients with head and neck squamous cell carcinoma. Kulak Burun Bogaz Ihtisas Dergisi 17(3): 148-151, 2007

Elevated serum levels of malondialdehyde in patients with squamous cell carcinoma of the head and neck. Proceedings of the American Association for Cancer Research Annual Meeting 35(0): 94, 1994

Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Research 25(4): 2761-2765, 2005

Chemokine receptor 7 enhances cell chemotaxis and migration of metastatic squamous cell carcinoma of head and neck through activation of matrix metalloproteinase-9. Oncology Reports 32(2): 794-800, 2015